The relationship between lymphocyte subsets and clinico-pathological determinants of survival in patients with primary operable invasive ductal breast cancer

British Journal of Cancer

Volumn 109, Issue 6, 2013, Pages 1676-1684

  Mohammed, Z M A ^a,b   Going, J J ^a   Edwards, J ^c   Elsberger, B ^d   Mcmillan, D C ^a  

^a UNIVERSITY OF GLASGOW   (United Kingdom)

^b OMAR AL MUKHTAR UNIVERSITY   (Libyan Arab Jamahiriya)

^c WESTERN INFIRMARY   (United Kingdom)

^d UNIVERSITY OF DUNDEE   (United Kingdom)

Author keywords

[No Author keywords available]

Indexed keywords

ADULT; ARTICLE; BREAST CARCINOMA; CANCER SPECIFIC SURVIVAL; CD8+ T LYMPHOCYTE; CONTROLLED STUDY; FOLLOW UP; HUMAN; HUMAN CELL; HUMAN TISSUE; INFLAMMATORY CELL; INFLAMMATORY INFILTRATE; LYMPH VESSEL METASTASIS; LYMPHOCYTE SUBPOPULATION; MACROPHAGE; MAJOR CLINICAL STUDY; NEUTROPHIL; PRIORITY JOURNAL;

BREAST NEOPLASMS; CARCINOMA, DUCTAL, BREAST; FEMALE; HUMANS; IMMUNOHISTOCHEMISTRY; LYMPHOCYTE SUBSETS; MIDDLE AGED; NEOPLASM GRADING; NEOPLASM INVASIVENESS; SURVIVAL ANALYSIS; TISSUE ARRAY ANALYSIS;

EID: 84884589344     PISSN: 00070920     EISSN: 15321827     Source Type: Journal    
DOI: 10.1038/bjc.2013.493     Document Type: Article

References (27)

1. Baker K, Lachapelle J, Zlobec I, Bismar TA, Terracciano L, Foulkes WD (2011) Prognostic significance of CD8+ T lymphocytes in breast cancer depends upon both oestrogen receptor status and histological grade. Histopathology 58(7): 1107-1116.
2. Bindea G, Mlecnik B, Fridman WH, Galon J (2011) The prognostic impact of anti-cancer immune response: A novel classification of cancer patients. Semin Immunopathol 33(4): 335-340.
3. Cancerstats (2011) 25-6-2012. Ref type: Online Source
4. Carlomagno C, Perrone F, Lauria R, de Laurentiis M, Gallo C, Morabito A, Pettinato G, Panico L, Bellelli T, Apicella A (1995) Prognostic significance of necrosis, elastosis, fibrosis and inflammatory cell reaction in operable breast cancer. Oncology 52(4): 272-277.
5. Carter D, Pipkin RD, Shepard RH, Elkins RC, Abbey H (1978) Relationship of necrosis and tumor border to lymph node metastases and 10-year survival in carcinoma of the breast. Am J Surg Pathol 2(1): 39-46.
6. Colotta F, Allavena P, Sica A, Garlanda C, Mantovani A (2009) Cancer-related inflammation, the seventh hallmark of cancer: Links to genetic instability. Carcinogenesis 30(7): 1073-1081.
7. Costes V, Magen V, Legouffe E, Durand L, Baldet P, Rossi JF, Klein B, Brochier J (1999) The Mi15 monoclonal antibody (anti-syndecan-1) is a reliable marker for quantifying plasma cells in paraffin-embedded bone marrow biopsy specimens. Hum Pathol 30(12): 1405-1411[pii].
8. Crawford A, Macleod M, Schumacher T, Corlett L, Gray D (2006) Primary T cell expansion and differentiation in vivo requires antigen presentation by B cells. J Immunol 176(6): 3498-3506[pii].
9. DeNardo DG, Brennan DJ, Rexhepaj E, Ruffell B, Shiao SL, Madden SF, Gallagher WM, Wadhwani N, Keil SD, Junaid SA, Rugo HS, Hwang ES, Jirstroem K, West BL, Coussens LM (2011) Leukocyte complexity predicts breast cancer survival and functionally regulates response to chemotherapy. Cancer Discovery 1(1): 54-67.
10. DeNardo DG, Coussens LM (2007) Inflammation and breast cancer. Balancing immune response: Crosstalk between adaptive and innate immune cells during breast cancer progression. Breast Cancer Res 9(4): 212.
11. Galon J, Costes A, Sanchez-Cabo F, Kirilovsky A, Mlecnik B, Lagorce-Pages C, Tosolini M, Camus M, Berger A, Wind P, Zinzindohoue F, Bruneval P, Cugnenc PH, Trajanoski Z, Fridman WH, Pages F (2006) Type, density, and location of immune cells within human colorectal tumors predict clinical outcome. Science 313(5795): 1960-1964[pii].
12. Hanahan D, Weinberg RA (2011) Hallmarks of cancer: The next generation. Cell 144(5): 646-674.
13. Klintrup K, Makinen JM, Kauppila S, Vare PO, Melkko J, Tuominen H, Tuppurainen K, Makela J, Karttunen TJ, Makinen MJ (2005) Inflammation and prognosis in colorectal cancer. Eur J Cancer 41(17): 2645-2654.
14. Lal P, Tan LK, Chen B (2005) Correlation of HER-2 status with estrogen and progesterone receptors and histologic features in 3,655 invasive breast carcinomas. Am J Clin Pathol 123(4): 541-546.
15. Liu S, Lachapelle J, Leung S, Gao D, Foulkes WD, Nielsen TO (2012) CD8+ lymphocyte infiltration is an independent favorable prognostic indicator in basal-like breast cancer. Breast Cancer Res 14(2): R48.
16. Mahmoud SM, Lee AHS, Paish EC, Macmillan RD, Ellis IO, Green AR (2011a) The prognostic significance of B lymphocytes in invasive carcinoma of the breast. Breast Cancer Res Treat 132(2): 545-553.
17. Mahmoud SM, Paish EC, Powe DG, Macmillan RD, Grainge MJ, Lee AHS, Ellis IO, Green AR (2011b) Tumor-infiltrating CD8+ lymphocytes predict clinical outcome in breast cancer. J Clin Oncol 29(15): 1949-1955.
18. Mohammed ZM, Edwards J, Orange C, Mallon E, Doughty JC, McMillan DC, Going JJ (2012a) Breast cancer outcomes by steroid hormone receptor status assessed visually and by computer image analysis. Histopathology 61(2): 283-292.
19. Mohammed ZM, Going JJ, Edwards J, Elsberger B, Doughty JC, McMillan DC (2012b) The relationship between components of tumour inflammatory cell infiltrate and clinicopathological factors and survival in patients with primary operable invasive ductal breast cancer. Br J Cancer 107(5): 864-873.
20. Mohammed ZM, Going JJ, Edwards J, McMillan DC (2012c) The role of the tumour inflammatory cell infiltrate in predicting recurrence and survival in patients with primary operable breast cancer. Cancer Treat Rev 38(8): 943-955.
21. Mohammed ZM, Going JJ, McMillan DC, Orange C, Mallon E, Doughty JC, Edwards J (2012d) Comparison of visual and automated assessment of HER2 status and their impact on outcome in primary operable invasive ductal breast cancer. Histopathology 61(4): 675-684.
22. Mohammed ZM, McMillan DC, Elsberger B, Going JJ, Orange C, Mallon E, Doughty JC, Edwards J (2012e) Comparison of Visual and automated assessment of Ki-67 proliferative activity and their impact on outcome in primary operable invasive ductal breast cancer. Br J Cancer 106(2): 383-388.
23. Parkin DM, Bray F, Ferlay J, Pisani P (2001) Estimating the world cancer burden: Globocan 2000. Int J Cancer 94(2): 153-156.
24. Richards CH, Roxburgh CS, Anderson JH, McKee RF, Foulis AK, Horgan PG, McMillan DC (2012) Prognostic value of tumour necrosis and host inflammatory responses in colorectal cancer. Br J Surg 99(2): 287-294.
25. Tedder TF, Engel P (1994) CD20: A regulator of cell-cycle progression of B lymphocytes. Immunol Today 15(9): 450-454.
26. Vakkila J, Lotze MT (2004) Inflammation and necrosis promote tumour growth. Nat Rev Immunol 4(8): 641-648.
27. Youinou P, Jamin C, Saraux A (2007) B-cell: A logical target for treatment of rheumatoid arthritis. Clin Exp Rheumatol 25(2): 318-328.